Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
Primary objective:
- to characterize the pharmacokinetic and the pharmacodynamic profile after intravenous
bolus injection of unfractionated heparin (UFH) after repeated sc 100 IU anti-Xa/kg
(corresponding to 1 mg/kg) twice a day during 2.5 days (every 12±2hrs) administrations
of enoxaparin in Caucasian healthy subjects.
Secondary objective(s):
- to compare the pharmacokinetic and the pharmacodynamic profile between 3 different
timing of administration of the UFH
- to assess the tolerability of the different anticoagulation protocols